Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN-2024004 is a small molecule drug candidate being developed by Daehan Nupharm, a South Korean pharmaceutical company, for the treatment of liver disease. Currently in the formulation development stage, the project is part of Daehan Nupharm's research and development pipeline, which focuses on metabolic and hepatic health. The company often specializes in developing improved management drugs (IMDs) and new formulations of existing compounds to enhance therapeutic efficacy or patient compliance. While the specific biological target and mechanism of action for DN-2024004 have not been publicly disclosed, the candidate aims to address unmet needs in liver health, potentially targeting conditions such as non-alcoholic fatty liver disease (NAFLD) or providing hepatoprotective effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DN-2024004.